First National Bank of Omaha Takes $2.82 Million Position in United Therapeutics Corporation $UTHR

First National Bank of Omaha purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 5,198 shares of the biotechnology company’s stock, valued at approximately $2,816,000.

A number of other hedge funds have also bought and sold shares of the company. Meeder Advisory Services Inc. bought a new stake in United Therapeutics in the second quarter valued at about $346,000. Meeder Asset Management Inc. bought a new position in United Therapeutics during the 2nd quarter worth approximately $5,004,000. Citizens Financial Group Inc. RI bought a new position in United Therapeutics during the 2nd quarter worth approximately $391,000. BlackRock Inc. acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $2,868,735,000. Finally, Pallas Capital Advisors LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $1,207,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $506.59, for a total value of $4,812,605.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $164,359,579.37. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,356,182.60. This represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 452,575 shares of company stock worth $245,684,184. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on UTHR shares. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America decreased their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Royal Bank Of Canada decreased their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Price Performance

UTHR opened at $518.27 on Wednesday. The stock’s 50 day moving average price is $534.53 and its 200 day moving average price is $536.74. The stock has a market cap of $22.23 billion, a P/E ratio of 18.54, a P/E/G ratio of 1.69 and a beta of 0.59. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the firm posted $6.41 EPS. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.